These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 34758945)

  • 1. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
    Garcia-Manero G; Döhner H; Wei AH; La Torre I; Skikne B; Beach CL; Santini V
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):236-250. PubMed ID: 34758945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
    Ravandi F; Roboz GJ; Wei AH; Döhner H; Pocock C; Selleslag D; Montesinos P; Sayar H; Musso M; Figuera-Alvarez A; Safah H; Tse W; Sohn SK; Hiwase D; Chevassut T; Pierdomenico F; La Torre I; Skikne B; Bailey R; Zhong J; Beach CL; Dombret H
    J Hematol Oncol; 2021 Aug; 14(1):133. PubMed ID: 34454540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
    Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
    Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Feld J; Tremblay D; Navada SC; Silverman LR
    Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cogle CR; Scott BL; Boyd T; Garcia-Manero G
    Oncologist; 2015 Dec; 20(12):1404-12. PubMed ID: 26463870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
    Ravandi F; Döhner H; Wei AH; Montesinos P; Pfeilstöcker M; Papayannidis C; Lai Y; Wang K; See WL; de Menezes DL; Petrlik E; Prebet T; Roboz GJ
    Br J Haematol; 2024 Mar; 204(3):877-886. PubMed ID: 37952982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
    Wei AH; Döhner H; Pocock C; Montesinos P; Afanasyev B; Dombret H; Ravandi F; Sayar H; Jang JH; Porkka K; Selleslag D; Sandhu I; Turgut M; Giai V; Ofran Y; Kizil Çakar M; Botelho de Sousa A; Rybka J; Frairia C; Borin L; Beltrami G; Čermák J; Ossenkoppele GJ; La Torre I; Skikne B; Kumar K; Dong Q; Beach CL; Roboz GJ;
    N Engl J Med; 2020 Dec; 383(26):2526-2537. PubMed ID: 33369355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
    Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
    J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.
    Keating GM
    Drugs; 2012 May; 72(8):1111-36. PubMed ID: 22571445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
    Adès L; Itzykson R; Fenaux P
    Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
    Scott LJ
    Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
    de Lima M; Oran B; Champlin RE; Papadopoulos EB; Giralt SA; Scott BL; William BM; Hetzer J; Laille E; Hubbell B; Skikne BS; Craddock C
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2017-2024. PubMed ID: 29933073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
    Roboz GJ; Montesinos P; Selleslag D; Wei A; Jang JH; Falantes J; Voso MT; Sayar H; Porkka K; Marlton P; Almeida A; Mohan S; Ravandi F; Garcia-Manero G; Skikne B; Kantarjian H
    Future Oncol; 2016 Feb; 12(3):293-302. PubMed ID: 26785287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Pasvolsky O; Saliba RM; Popat UR; Alousi A; Mehta R; Yeh J; Al-Atrash G; Adeel M; Ramdial J; Marin D; Rondon G; Kebriaei P; Champlin R; Daver N; Dinardo C; Short NJ; Shpall EJ; Oran B
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e196-e204. PubMed ID: 38403505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.